OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
NEWTON, Mass., March 07, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2015 financial results and provide a company update on Monday, March 14, 2016. Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to discuss the financial results and recent business developments.
To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 59463471. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, investors.karyopharm.com/events.cfm. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of inflammation, autoimmune disease, neurological disorders, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
